Landmarks across the country go Blue for Colorectal Cancer Awareness Month
March 03, 2023 02:56 ET
|
Colon Cancer Coalition
Minneapolis, March 03, 2023 (GLOBE NEWSWIRE) -- In recognition of Colorectal Cancer Awareness Month, civic, public, and private buildings and landmarks across the United States are slated to go BLUE...
United in the Fight Against Colorectal Cancer
March 01, 2023 17:42 ET
|
Fight Colorectal Cancer
Springfield, Mo., March 01, 2023 (GLOBE NEWSWIRE) -- On the heels of the White House declaring March as Colorectal Cancer Awareness Month, urging the public to get screened, national advocacy...
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
March 01, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
For Colorectal Cancer Awareness Month, the Colon Cancer Coalition invites the country to Talk Sh!t to save lives
February 28, 2023 18:58 ET
|
Colon Cancer Coalition
Created in conjunction with BeautifulBeast, an independent cross-cultural agency, “Talking Sh!t Saves Lives” lives predominantly on Twitter, with the support of radio PSAs, digital videos, social...
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
February 28, 2023 08:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that...
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
February 21, 2023 03:01 ET
|
Mainz BioMed NV
Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY...
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
February 15, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Chemotherapy At Home Services Market Research Report 2022: Strategic Partnerships and Collaborations Fueling Market Growth
February 03, 2023 07:33 ET
|
Research and Markets
Dublin, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The "Chemotherapy At Home Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Product (Chemotherapy...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
January 19, 2023 17:00 ET
|
Compass Therapeutics
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the...
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
January 18, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, US and MAINZ, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early...